These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. Jain N; Khoury JD; Pemmaraju N; Kollipara P; Kantarjian H; Verstovsek S Blood; 2013 Nov; 122(19):3387-8. PubMed ID: 24203930 [No Abstract] [Full Text] [Related]
44. Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up. Srinivasan A; Scordino T; Baker A J Pediatr Hematol Oncol; 2019 May; 41(4):334-335. PubMed ID: 30807397 [No Abstract] [Full Text] [Related]
45. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Cools J; Quentmeier H; Huntly BJ; Marynen P; Griffin JD; Drexler HG; Gilliland DG Blood; 2004 Apr; 103(7):2802-5. PubMed ID: 14630792 [TBL] [Abstract][Full Text] [Related]
46. "Likely to be missed if unsuspected": Sharma P; Khaire NS; Sreedharanunni S; Malhotra P; Varma N J Cancer Res Ther; 2022; 18(1):316-317. PubMed ID: 35381811 [No Abstract] [Full Text] [Related]
47. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504 [TBL] [Abstract][Full Text] [Related]